Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma

Comes After Delay For Roxadustat In The US

Executive Summary

The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.

You may also be interested in...



Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma

With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.

Amgen Expects Quick, Broad Adoption Of Tezspire In Severe Asthma

Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.

Amgen And AstraZeneca Tout Fresh Tezepelumab Data

Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel